Journal of the American Society of Hypertension
Volume 2, Issue 1 , Pages 3-7, January 2008

Antiplatelet therapy for recurrent stroke prevention: newer perspectives based on (MATCH), (CHARISMA), and (ESPRIT)

This invited Review is based on Dr. Gorelick’s presentation at a symposium held at the American Society of Hypertension Annual Meeting, in Chicago, Illinois, May 21, 2007.

  • Philip B. Gorelick, MD, MPH

      Affiliations

    • Dr. Gorelick receives honoraria as a steering committee member for studies for Bayer and Boehringer Ingelheim companies, and as a speaker for Boehringer Ingelheim.
    • Corresponding Author InformationCorresponding author: Philip B. Gorelick, MD, MPH, Center for Stroke Research, Department of Neurology and Rehabilitation, University of Illinois College of Medicine at Chicago, 912 S. Wood Street Room 855N, Chicago, Illinois 60612. Tel: 312-996-1757; fax: 312-413-1388.

Center for Stroke Research and Department of Neurology and Rehabilitation, University of Illinois College of Medicine at Chicago, Chicago, Illinois, USA

Received 25 June 2007; accepted 24 July 2007.

Abstract 

Antiplatelet therapy is an important component of our armamentarium for recurrent stroke prevention. Aspirin is a safe and effective antiplatelet drug for recurrent stroke prevention, however, it has been challenged recently by the thienopyridine derivative, clopidogrel, and the combination agent, aspirin plus extended release dipyridamole. In this review, we discuss recent studies of thienopyridine derivatives and aspirin plus extended-release dipyridamole in stroke prevention and evidence-based guidelines for the administration of these agents in practice for recurrent stroke prevention.

Keywords: Antiplatelet therapy, recurrent stroke prevention

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1933-1711(07)00163-5

doi:10.1016/j.jash.2007.07.003

Journal of the American Society of Hypertension
Volume 2, Issue 1 , Pages 3-7, January 2008

Article Tools